Nykredit A/S’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$58.1K Hold
1,793
– – ﹤0.01% 1469
2026
Q2
$66.7K Buy
+1,793
New +$57.9K ﹤0.01% 1430

Other funds holding CLDX

Nykredit A/S's CLDX Position: Q3 2026 in Review

Nykredit A/S held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 1,793 shares worth $58.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

Nykredit A/S first reported a position in CLDX in Q2 2026 and has held it in 2 quarters since. The position peaked at $66.7K in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Nykredit A/S held 1,793 shares of Celldex Therapeutics worth $58.1K as of Q3 2026.
  • Nykredit A/S left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q3 2026, its #1469 holding.
  • Nykredit A/S first reported a position in Celldex Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Nykredit A/S's Celldex Therapeutics position peaked at $66.7K in Q2 2026.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Nykredit A/S's 13F filing for Q3 2026, filed 6 Nov 2026.